3013-07-8

Basic information

• Product Name: 1H-Benzimidazole-2-carboxaldehyde,1-methyl-,oxime(9CI)
• Synonyms: 1H-Benzimidazole-2-carboxaldehyde,1-methyl-,oxime(9CI)
• CAS NO: 3013-07-8
• Molecular Formula: C₉H₉N₃O
• Molecular Weight: 175.19
• Product Categories: BENZIMIDAZOLE
• Mol File: 3013-07-8.mol

Chemical Properties

• Melting Point: 218 °C(Solv: acetone (67-64-1))
• Boiling Point: 249.7°Cat760mmHg
• Flash Point: 104.8°C
• Appearance: /
• Density: 1.27g/cm³
• Vapor Pressure: 0.0226mmHg at 25°C
• Refractive Index: 1.644
• PKA: 10.34±0.30(Predicted)
• CAS DataBase Reference: 1H-Benzimidazole-2-carboxaldehyde,1-methyl-,oxime(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Benzimidazole-2-carboxaldehyde,1-methyl-,oxime(9CI)(3013-07-8)
• EPA Substance Registry System: 1H-Benzimidazole-2-carboxaldehyde,1-methyl-,oxime(9CI)(3013-07-8)

Safety Data

• Hazardous Substances Data: 3013-07-8(Hazardous Substances Data)

Usage

InChI:InChI=1/C9H9N3O/c1-12-8-5-3-2-4-7(8)11-9(12)6-10-13/h2-6,11H,1H3/b9-6-

Upstream product

• 3012-80-4 1-methyl-2-formyl-1H-benzimidazole 

Downstream Products

• 53332-79-9 2-aminomethyl-1-methylbenzimidazole dihydrochloride 

Relevant articles and documents

SPIRO-OXADIAZOLINE COMPOUNDS AS AGONISTS OF α-7-NICOTINIC ACETYLCHOLINE RECEPTORS

The present invention relates to novel spiro-oxadiazoline compounds that are suitable as agonists or partial agonists of a7-nAChR, and pharmaceutical compositions of the same, methods of preparing these compounds and compositions, and the use of these compounds and compositions in methods of maintaining, treating and/or improving cognitive function. In particular, methods of administering a spiro-oxadiazoline cx7-nAChR agonist or partial agonist, to a patient in need thereof, for example a patient with a cognitive deficiency and/or a desire to enhance cognitive function, that may derive a benefit therefrom.

Mechanochemical and conformational study of N-heterocyclic carbonyl-oxime transformations

New mechanochemical pathways for the transformation of six N-heterocyclic carbonyl compounds into oximes using hydroxylamine hydrochloride were explored. Reactions were performed first without any base since the heterocyclic moieties (imidazole, benzimidazole, pyridine and quinuclidine) have an intrinsic basic nitrogen atom. This green, solvent free method was suitable for all compounds (up to quantitative yields) except for N-benzyl substituted imidazole and benzimidazole-2-carbaldehyde. For the slower reacting aldehydes, reactions with liquid assisted grinding and addition of sodium hydroxide were performed as well. Conformational analysis and quantum-chemical calculations revealed steric and electronic reasons for the lower reactivity of N-benzyl substituted derivatives.

2-(1H-INDAZOL-6-YLAMINO)-BENZAMIDE COMPOUNDS AS PROTEIN KINASES INHIBITORS USEFUL FOR THE TREATMENT OF OPHTALMIC DISEASES

Indazole compounds that modulate and/or inhibit the ophthalmic diseases and the activity of certain protein kinases are described. These compounds and pharmaceutical compositions containing them are capable of mediating tyrosine kinase signal transduction and thereby modulate and/or inhibit unwanted cell proliferation. The invention is also directed to the therapeutic or prophylactic use of pharmaceutical compositions containing such compounds, and to methods of treating ophthalmic diseases and cancer and other disease states associated with unwanted angiogenesis and/or cellular proliferation, such as diabetic retinopathy, neovascular glaucoma,rheumatoid arthritis, and psoriasis, by administering effective amounts of such compounds.